Coherus Oncology, Inc.
CHRS
NASDAQ·Healthcare·Biotechnology·Mkt cap $219.4M
$1.42
▲ +3.65%
P/E
-1.41
Mkt Cap
$219.4M
52-Wk Range
$1.09–$2.62
52-Week Range
$1.09 - $2.62
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 3.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Differentiated next-generation PD-1 inhibitor (LOQTORZI) with potential for improved efficacy and safety profiles
- Established biosimilar commercialization expertise generating near-term revenue while funding oncology pipeline
- Strategic partnerships with Junshi Biosciences, Genentech, and GSK providing development support and market access
- Focused pipeline of highly specific monoclonal antibodies targeting underexploited immune checkpoints (IL-27, CCR8, ILT4, CD112R)
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
High-margin business model (185% net margin)
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+0.0% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CHRS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of -$0.19 vs -$0.25 consensus (+24.0% surprise). Revenue of $14.3M vs $14.4M expected (-0.7%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+24.0%
Revenue trend · last 8Q
—
-41%
+229%
-84%
-84%
-76%
+62%
+40%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$70.8M
$54.1M
$7.6M
$10.3M
$11.6M
$12.7M
$12.3M
$14.3M
Margins · last 8Q
Gross
-53.2%
Operating
—
Profit
-144.2%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CHRS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related